Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmagen cz s.r.o. - abirateronacetat - filmovertrukne tabletter - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

day zero ehf. - abirateronacetat - filmovertrukne tabletter - 500 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - zytiga er angivet med prednison eller prednisolon for:behandling af metastatisk kastration resistent prostatakræft hos voksne mænd, der er asymptomatiske eller mildt symptomatisk efter svigt af androgen deprivation terapi i hvem kemoterapi er endnu ikke klinisk indicatedthe behandling af metastatisk kastration resistent prostatakræft hos voksne mænd, hvis sygdommen har udviklet sig på eller efter en docetaxel-baseret kemoterapi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - abiraterone acetat - prostatiske neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatiske neoplasmer - terapeutiske radioaktive lægemidler - xofigo er indiceret til behandling af voksne med kastreringsresistent prostatacancer, symptomatiske knoglemetastaser og ingen kendte viscerale metastaser.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

institut produits synthése (ipsen) ab - triptorelin - depotinjektionsvæske, pulver og solvens til suspension - 11,25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - triptorelin - depotinjektionsvæske, pulver og solvens til suspension - 11,25 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - olaparib - Æggestokkene neoplasmer - antineoplastiske midler - Æggestokkene cancerlynparza er angivet som monoterapi til:vedligeholdelse behandling af voksne patienter med avanceret (figo faser iii og iv) brca1/2-muterede (germline og/eller somatiske) high-grade epitelial ovariecancer, æggeleder eller primær peritoneal cancer, der er i reaktion (hel eller delvis) efter afslutningen af første linje platin-baseret kemoterapi. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 og 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. patienter bør have, der tidligere er blevet behandlet med en antracyklin og en taxane i (neo)adjuvans eller metastatisk indstilling, medmindre patienter, der ikke var egnet til disse behandlinger (se afsnit 5. patienter med hormon receptor (hr)-positiv brystkræft bør også have udviklet sig på eller efter forudgående endokrine terapi, eller anses uegnet til at endokrine terapi. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - leuprorelinacetat - implantat, fyldt injektionssprøjte - 3,6 mg